(+/-)-4,5,6,7-tetrahydro-2H-izoindol-5-ylmethanamine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: (+/-)-4,5,6,7-tetrahydro-2H-izoindol-5-ylmethanamine
• 英文别名: (4,5,6,7-Tetrahydro-2H-isoindol-5-yl)methanamine；4,5,6,7-tetrahydro-2H-isoindol-5-ylmethanamine
• 化学式: C₉H₁₄N₂
• mdl: MFCD09263871
• 分子量: 150.224
• InChiKey: AHQVWVILFQJKSM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.555
• 拓扑面积：
  41.8
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  (+/-)-N-[(2-acetyl-4,5,6,7-tetrahydro-2H-izoindol-5-yl)methyl]acetamide 在 sodium hydroxide 、 水 作用下， 以 甲醇 为溶剂， 反应 16.0h， 以74%的产率得到(+/-)-4,5,6,7-tetrahydro-2H-izoindol-5-ylmethanamine
  参考文献：
  名称：

  A general synthetic approach to novel conformationally restricted arginine side chain mimetics

  摘要：

  A general synthesis of several novel partially saturated, conformationally restricted heterobicyclic arginine side chain mimetics is described. These compounds are interesting peptidomimetic building blocks for incorporation into trypsin-like serine protease inhibitors. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(01)01243-1

文献信息

• Thrombin inhibitors
  申请人：Marsic Peterlin Lucija

  公开号：US20050165034A1

  公开（公告）日：2005-07-28

  Novel thrombin inhibitors of the formula I (I)and pharmaceutically acceptable salts thereof are described wherein the substituents in the description have the specific meanings. The compounds are useful as thrombin inhibitors.

  本发明提供了式I（I）及其药学上可接受的盐的新型凝血酶抑制剂，其中描述中的取代基具有特定的含义。这些化合物可用作凝血酶抑制剂。
• US7524871B2
  申请人：——

  公开号：US7524871B2

  公开（公告）日：2009-04-28
• A general synthetic approach to novel conformationally restricted arginine side chain mimetics
  作者：Lucija Peterlin-Mašič、Andreja Jurca、Petra Marinko、Anita Jančar、Danijel Kikelj

  DOI：10.1016/s0040-4020(01)01243-1

  日期：2002.2

  A general synthesis of several novel partially saturated, conformationally restricted heterobicyclic arginine side chain mimetics is described. These compounds are interesting peptidomimetic building blocks for incorporation into trypsin-like serine protease inhibitors. (C) 2002 Elsevier Science Ltd. All rights reserved.